Duchenne Muscular Dystrophy
Released: May 15, 2018
Defense Health Program
Department of Defense Duchenne Muscular Dystrophy Research Program
Anticipated Funding Opportunities for Fiscal Year 2018 (FY18)
The FY18 Defense Appropriations provides $3.2 million (M) to the Department of Defense Duchenne Muscular Dystrophy Research Program (DMDRP) to support innovative, high-impact Duchenne muscular dystrophy research. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, J9 Research and Development Directorate manages the Defense Health Program Research, Development, Test, and Evaluation appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).
The DMDRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications. FY18 DMDRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in June 2018. Pre-application and application deadlines will be available when the Program Announcements are released. This pre-announcement should not be construed as an obligation by the government.
All applications for the FY18 DMDRP funding opportunities are required to address at least one of the following Focus Areas:
- Bone, cardiac, central nervous system (CNS), and/or gastrointestinal tract studies, including identifying mechanisms of pathology and therapeutic interventions
- Translational and clinical studies, novel interventions, and drug and biologic delivery technologies designed to improve care and quality of life in areas such as:
- Cognitive function
- Gastrointestinal issues
- Psychosocial issues
- Pulmonology (including sleep-focused studies)
- Skeletal muscle
- Assessment of clinical trial tools and outcome measures, such as:
- Discovery and qualification of pharmacodynamic, prognostic, and predictive biomarkers
- Novel clinical outcome assessments
- Patient-centered outcomes (e.g., quality of life, activities of daily living)
- Potential surrogate markers
- Secondary data analysis that helps to address clinical research tool validation and/or to understand natural history
- Extension or expansion of existing preclinical translational data in support of a specific therapeutic development path (such as optimizing delivery to target tissues, including drug exposure, independent replication, and comparative studies)
|Award Mechanism||Eligibility||Key Mechanism Elements||Funding|
|Investigator-Initiated Research Award||Principal Investigator: Must be an independent investigator at or above the level of Assistant Professor (or equivalent).
Optional Nested Resident or Medical Student Trainee: Resident trainee must be enrolled in an accredited residency program. Medical student trainee must be enrolled in a nationally accredited (or equivalent) medical school. Trainees must be able to devote a minimum of 40% level of effort.
Optional Interdisciplinary Collaborator: Must be an independent investigator at or above the level of Assistant Professor (or equivalent), whose primary training, research, and experience is in a different field than the PI. The collaborator is required to devote a minimum of 10% level of effort to this project.
|Career Development Award||Principal Investigator: Must be research (Ph.D.) or physician (M.D.) scientists at an early stage of their research careers with a minimum of 2 years post terminal degree (excluding medical residency or family medical leave), working to become independent investigators who exhibit a strong desire to pursue careers in Duchenne research.
Mentor: Must hold a position at or above the level of an Associate Professor (or equivalent).
A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.
Applications must be submitted through the Federal Government’s single-entry portal, Grants.gov. Submission deadlines are not available until the Program Announcements are released. For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the DMDRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).
Point of Contact:
CDMRP Public Affairs
Last updated Thursday, May 26, 2022